Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | The importance of MRD assessment in all phases of ALL treatment

Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease (MRD) assessment in predicting the long-term effects of therapy in acute lymphoblastic leukemia (ALL) patients, and the steps that should be followed if a patient is MRD-positive after the administration of CAR T-cell therapy or other forms of treatment. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.